๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

*401 Distribution and Significance of EZH2 Mutations in MDS and Related Myeloid Malignancies

โœ Scribed by Hideki Makishima; Anna Jankowska; Hadrian Szpurka; Alan List; Michael McDevitt; Kathryn Guinta; Mehdi A. Keddache; Christine O'Keefe; Mikkael A. Sekeres; Jaroslaw Maciejewski

Book ID
119218755
Publisher
Elsevier
Year
2011
Tongue
English
Weight
128 KB
Volume
11
Category
Article
ISSN
2152-2650

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

RAS, FLT3, and TP53 mutations in therapy
RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7
โœ Lucy E. Side; Nicole P. Curtiss; Kathryn Teel; Christian Kratz; Pauline W. Wang; ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 114 KB

## Abstract Oncogenic mutations in the __KRAS2__, __NRAS__, or __FLT3__ gene are detected in more than 50% of patients with de novo acute myeloid leukemia (AML). __RAS__ mutations are also prevalent in de novo myelodysplastic syndrome (MDS), especially chronic myelomonocytic leukemia and juvenile m